Seizures in low-grade gliomas: Natural history, pathogenesis, and outcome after treatments

Neuro-Oncology

Volumn 14, Issue SUPPL.4, 2012, Pages

  Rudà, Roberta ^a   Bello, Lorenzo ^b   Duffau, Hugues ^c   Soffietti, Riccardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIV MONTPELLIER   (France)

Author keywords

antiepileptic drugs; chemotherapy; diffuse gliomas; epileptogenesis; glioneuronal tumors; radiotherapy; seizures; surgery

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LOMUSTINE; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; ELECTROCORTICOGRAPHY; EPILEPTOGENESIS; GLIOMA; HUMAN; MEDICAL HISTORY; MOLECULARLY TARGETED THERAPY; NEUROIMAGING; PATHOGENESIS; PREOPERATIVE PERIOD; PROPHYLAXIS; SEIZURE; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

ANTICONVULSANTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOPLASM GRADING; SEIZURES; TREATMENT OUTCOME;

EID: 84868016792     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos199     Document Type: Article

References (130)

1. Liigant A, Haldre S, Oun A, et al. Seizure disorders in patients with brain tumors. Eur Neurol. 2001;45:46-51. (Pubitemid 32041387)
2. Lynam LM, Lyons MK, Drazkowski JF, et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg. 2007;109:634-638. (Pubitemid 47016762)
3. Rosati A, Tomassini A, Pollo B, et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol. 2009;93:395-400.
4. Rudà R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol. 2010;22:611-620.
5. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54:514-520. (Pubitemid 37176548)
6. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159-168. (Pubitemid 38229950)
7. Smits A, Duffau H. Seizures and the natural history of World Health Organization grade II gliomas: a review. Neurosurgery. 2011;68:1326-1333.
8. Kahlenberg CA, Fadul CE, Roberts DW, et al. Seizure prognosis of patients with low-grade tumors [published online ahead of print June 22, 2012]. Seizure. 2012; doi:10.1016/j.seizure.2012.05.014.
9. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15:1294-1301. (Pubitemid 27167360)
10. Pignatti F, van den Bent MJ, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084. (Pubitemid 34408798)
11. Danfors T, Ribom D, Berntsson SG, et al. Epileptic seizures and survival in early disease of grade 2 gliomas. Eur J Neurol. 2009;16:823-831.
12. Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17:1124-1133.
13. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421-430. (Pubitemid 46551867)
14. Duffau H, Capelle L, Lopes M, et al. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionec-tomy. Acta Neurochir. 2002;144:563-572.
15. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108:227-235. (Pubitemid 351213284)
16. You G, Sha ZY, Yan W, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro-Oncol. 2012;14:230-241.
17. Prayson RA. Diagnostic challenges in the evaluation of chronic epilepsy-related surgical neuropathology. Am J Surg Pathol. 2010;34:e1-e13.
18. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
19. Luyken C, Blümcke I, Fimmers R, et al. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer. 2004;101:146-155. (Pubitemid 38812434)
20. Majores M, von Lehe M, Fassunke J, et al. Tumor recurrence and malignant progression of gangliogliomas. Cancer. 2008;113:3355-3363.
21. Campos AR, Clusmann H, von Lehe M, et al. Simple and complex dys-embryoplastic neuroepithelial tumors (DNT) variants: clinical profile, MRI, and histopathology. Neuroradiology. 2009;51:433-443.
22. Blümcke I, Vinters HV, Armstrong D, et al. Malformations of cortical development and epilepsies: neuropathological findings with emphasis on focal cortical dysplasia. Epileptic Disord. 2009;11:181-193.
23. Kaloshi G, Psimaras D, Mokhtari K, et al. Supratentorial low-grade gliomas in older patients. Neurology. 2009;73:2093-2098.
24. Schramm J, Luyken C, Urbach H, et al. Evidence for a clinically distinct new subtype of grade II astrocytomas in patients with long-term epilepsy. Neurosurgery. 2004;55:340-347. (Pubitemid 39014523)
25. Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010;67:336-342.
26. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir. 2000;142:1-15. (Pubitemid 30068270)
27. Schaller B, Rüegg SJ. Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia. 2003;44:1223-1232. (Pubitemid 37100049)
28. Ferrier CH, Aronica E, Leijten FS, et al. Electrocorticographic discharge patterns in glioneuronal tumors and focal cortical dysplasia. Epilepsia. 2006;47:1477-1486. (Pubitemid 44393860)
29. Rajneesh KF, Binder DK. Tumor-associated epilepsy. Neurosurg Focus. 2009;27:E4.
30. Aronica E, Gorter JA, Redeker S, et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. Neuropathol Appl Neurobiol. 2005;31:280-291. (Pubitemid 40769527)
31. Bartolomei F, Bosma I, Klein M, et al. How do brain tumors alter functional connectivity? A magnetoencephalography study. Ann Neurol. 2006;59:128-138. (Pubitemid 43042879)
32. Bosma I, Douw L, Bartolomei F, et al. Synchronized brain activity and neurocognitive function in patients with low-grade glioma: a magneto-encephalography study. Neuro-Oncol. 2008;10:734-744.
33. Douw L, van Dellen E, de Groot M, et al. Epilepsy is related to theta band brain connectivity and network topology in brain tumor patients. BMC Neurosci. 2010;11:103.
34. Ponten SC, Bartolomei F, Stam CJ. Small-world networks and epilepsy: graph theoretical analysis of intracerebrally recorded mesial temporal lobe seizures. Clin Neurophysiol. 2007;118:918-992.
35. Shamji MF, Fric-Shamji EC, Benoit BG. Brain tumors and epilepsy: path-ophysiology of peritumoral changes. Neurosurg Rev. 2009;32:275-284.
36. Aronica E, Gorter JA, Jansen GH, et al. Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol. 2001;101:449-459. (Pubitemid 32600134)
37. Chernov MF, Kubo O, Hayashi M, et al. Proton MRS of the peritumoral brain. J Neurol Sci. 2005;228:137-142. (Pubitemid 40202958)
38. Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain. 2007;130:535-547. (Pubitemid 46181106)
39. Ricci R, Bacci A, Tugnoli V, et al. Metabolic findings on 3T 1H-MR spec-troscopy in peritumoral brain edema. Am J Neuroradiol. 2007;28:1287-1291. (Pubitemid 47309660)
40. Lyons SA, Chung WJ, Weaver AK, et al. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 2007;67:9463-9471. (Pubitemid 47535936)
41. Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem. 2008;105:287-295. (Pubitemid 351490026)
42. Sontheimer H. An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med. 2008;233:779-791.
43. Buckingham SC, Campbell SL, Haas BR, et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011;17:1269-1274.
44. Aronica E, Yankaya B, Jansen GH, et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol. 2001;27:223-237. (Pubitemid 32678675)
45. Maas S, Patt S, Schrey M, et al. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci. 2001;98:14687-14692. (Pubitemid 33121452)
46. Lee MC, Kang JY, Seol MB, et al. Clinical features and epileptogenesis of dysembryoplastic neuroepithelial tumor. Childs Nerv Syst. 2006;22:1611-1618.
47. Samadani U, Judkins AR, Akpalu A, et al. Differential cellular gene expression in ganglioglioma. Epilepsia. 2007;48:646-653. (Pubitemid 46587612)
48. Aronica E, Boer K, Becker A, et al. Gene expression profile analysis of epilepsy-associated gangliogliomas. Neuroscience. 2008;151:272-292.
49. Berntsson SG, Malmer B, Bondy ML, et al. Tumor-associated epilepsy and glioma: are there common genetic pathways? Acta Oncol. 2009;48:955-963.
50. Huang L, You G, Jiang T, et al. Correlation between tumor-related seizures and molecular genetic profile in 103 Chinese patients with low-grade gliomas: a preliminary study. J Neurol Sci. 2011;302:63-67.
51. Ben-Ari Y, Dudek FE. Primary and secondary mechanisms of epilepto-genesis in the temporal lobe: there is a before and an after. Epilepsy Curr. 2010;10:118-125.
52. Berger MS, Ghatan S, Haglund MM, et al. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticogra-phy during tumor resection. J Neurosurg. 1993;79:62-69. (Pubitemid 23182745)
53. Fried I, Kim JH, Spencer DD. Limbic and neocortical gliomas associated with intractable seizures: a distinct clinicopathological group. Neurosurgery. 1994;34:815-823.
54. Zaatreh MM, Firlik KS, Spencer DD, et al. Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome. Neurology. 2003;61:636-641. (Pubitemid 37082600)
55. Luyken C, Blümcke I, Fimmers R, et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia. 2003;44:822-830. (Pubitemid 36754008)
56. Choi JY, Chang JW, Park YG, et al. A retrospective study of the clinical outcomes and significant variables in the surgical treatment of temporal lobe tumor associated with intractable seizures. Stereotact Funct Neurosurg. 2004;82:35-42. (Pubitemid 38332941)
57. Bauer R, Dobesberger J, Unterhofer C, et al. Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy. Acta Neurochir. 2007;149:1211-1216. (Pubitemid 350265443)
58. Phi JH, Kim SK, Cho BK, et al. Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. Cancer. 2009;115:5771-5779.
59. Englot DJ, Berger MS, Barbaro NM, et al. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg. 2011;115:240-244.
60. Duffau H. Surgery of low-grade gliomas: towards a 'functional neuro-oncology'. Curr Opin Oncol. 2009;21:543-549.
61. Bello L, Fava E, Carrabba G, Papagno C, Gaini SM. Present day's standards in microsurgery of low-grade gliomas. Adv Tech Stand Neurosurg. 2010;35:113-157.
62. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100:2622-2626.
63. Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. J Neurosurg. 2011;115:232-239.
64. Blonski M, Taillandier L, Herbet G, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012;106:353-366.
65. Rudà R, Trevisan E, Soffietti R. Low-grade gliomas. In: Grisold, W, Soffietti, R, eds, Handbook of Clinical Neurology. Edinburgh: Elsevier; 2012;105:437-450.
66. Englot DJ, Berger MS, Barbaro NM, et al. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia. 2012;53:51-57.
67. Yang I, Chang EF, Han SJ, et al. Early surgical intervention in adult patients with ganglioglioma is associated with improved clinical seizure outcomes. J Clin Neurosci. 2011;18:29-33.
68. Zentner J, Wolf HK, Ostertun B, et al. Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatr. 1994;57:1497-1502.
69. Aronica E, Leenstra S, van Veelen CW et al. Glioneuronal tumors and medically intractable epilepsy: a clinical study with long-term follow-up of seizure outcome after surgery. Epilepsy Res. 2001;43:179-191. (Pubitemid 32204444)
70. Clusmann H, Schramm J, Kral T, et al. Prognostic factors and outcome after different types of resection for temporal lobe epilepsy. J Neurosurg. 2002;97:1131-1141. (Pubitemid 35253551)
71. Lombardi D, Marsh R, de Tribolet N. Low grade glioma in intractable epilepsy: lesionectomy versus epilepsy surgery. Acta Neurochir Suppl. 1997;68:70-74.
72. Giulioni M, Rubboli G, Marucci G, et al. Seizure outcome of epilepsy surgery in focal epilepsies associated with temporomesial glioneuronal tumors: lesionectomy compared with tailored resection. J Neurosurg. 2009;111:1275-1282.
73. Kurzwelly D, Herrlinger U, Simon M. Seizures in patients with low-grade gliomas: incidence, pathogenesis, surgical management, and pharmacotherapy. Adv Tech Stand Neurosurg. 2010;35:81-111.
74. Ghareeb F, Duffau H. Intractable epilepsy in paralimbic Word Health Organization Grade II gliomas: should the hippocampus be resected when not invaded by the tumor? J Neurosurg. 2012;116:1226-1234.
75. Pilcher WH, Silbergeld DL, Berger MS, et al. Intraoperative electrocorti-cography during tumor resection: impact on seizure outcome in patients with gangliogliomas. J Neurosurg. 1993;78:891-902. (Pubitemid 23159325)
76. Jooma R, Yeh HS, Privitera MD, Gartner M. Lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with complex partial seizures. J Neurosurg. 1995;83:231-236.
77. Sugano H, Shimizu H, Sunaga S. Efficacy of intraoperative electrocorti-cography for assessing seizure outcomes in intractable epilepsy patients with temporal-lobe-mass lesions. Seizure. 2007;16:120-127. (Pubitemid 46211170)
78. Rossi GF, Scerrati M, Roselli R. Epileptogenic cerebral low-grade tumors: effect of interstitial stereotactic irradiation on seizures. Appl Neurophysiol. 1985;48:127-132. (Pubitemid 16064582)
79. Warnke PC, Berlis A, Weyerbrock A, et al. Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas. Acta Neurochir. 1997;68:90-92.
80. Schröttner O, Unger F, Eder HG, et al. Gamma-knife radiosurgery of mesiotemporal tumour epilepsy observations and long-term results. Acta Neurochir. 2002;84:49-55.
81. Mathieu D, Kondziolka D, Niranjan A, et al. Gamma knife radiosurgery for refractory epilepsy caused by hypothalamic hamartomas. Stereotact Funct Neurosurg. 2006;84:82-87. (Pubitemid 44155929)
82. Kondziolka D, Lunsford LD, Flickinger JC, et al. The application of ster-eotactic radiosurgery to disorders of the brain. Neurosurgery. 2008;62:707-720.
83. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43:1599-1601. (Pubitemid 23230553)
84. Rudà R, Trevisan E, Magliola U, et al. Efficacy of radiation therapy on epileptic seizures of grade 2 and 3 gliomas: a retrospective study. [Abstract]. J Clin Oncol. 2011;29:2074.
85. van den Bent MJ, Afra D, de Witte O, et al. EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-990. (Pubitemid 41323034)
86. Mason W, Krol G, De Angelis LM. Low grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203-207. (Pubitemid 26156130)
87. Soffietti R, Rudà R, Bradac GB, et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43:1066-1073. (Pubitemid 28481106)
88. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolo-mide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715-1721. (Pubitemid 38029041)
89. Pace A, Vidiri A, Galiè E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14:1722-1726. (Pubitemid 38029042)
90. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatments for adults with low-grade oligodendrogliomas or oligoastrocyto-mas and correlation with chromosome 1 p deletions. J Clin Oncol. 2004;22:3133-3138. (Pubitemid 41103727)
91. Frenay MP, Fontaine D, Vandenbos F, et al. First-line nitrosourea-based chemotherapy in symptomatic nonresectable supratentorial pure low-grade astrocytomas. Eur J Neurol. 2005;12:685-690. (Pubitemid 41297830)
92. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-1836. (Pubitemid 46791397)
93. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. 2007;14:391-398. (Pubitemid 46481159)
94. Taillandier L, Duffau H. Epilepsy and insular grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus. 2009;27:E8.
95. Sherman JH, Moldovan K, Yeoh HK, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg. 2011;114:1617-1621.
96. Rudà R, Bertero L, Trevisan E, et al. Phase II trial of dose-dense temo-zolomide as initial treatment for progressive low-grade oligodendroglial tumors : a multicentric study of the Italian Association of Neuro-Oncology (AINO). [Abstract]. J Clin Oncol. 2012;30:2037.
97. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801-1811.
98. Franz DN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther. 2011;11:1181-1192.
99. Hildebrand J. Management of epileptic seizures. Curr Opin Oncol. 2004;16:314-317. (Pubitemid 38870035)
100. Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci. 1996;23:128-131. (Pubitemid 26186481)
101. Striano S, Striano P, Boccella P, et al. Tiagabine in glial tumors. Epilepsy Res. 2002;49:81-85. (Pubitemid 34304209)
102. Wagner GL, Wilms EB, Van Donselaar CA, Vecht Ch J. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure. 2003;12:585-586. (Pubitemid 37509054)
103. Maschio M, Albani F, Baruzzi A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol. 2006;80:97-100. (Pubitemid 44473268)
104. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol. 2006;78:99-102. (Pubitemid 43786667)
105. Maschio M, Dinapoli L, Zarabla A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol. 2008;86:61-70. (Pubitemid 350263434)
106. Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg. 2009;111:171-173.
107. Rosati A, Buttolo L, Stefini R, et al. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol. 2010;67:343-346.
108. Kerrigan S, Grant R. Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev. [Review]. 2011;8:CD008586.
109. Maschio M, Dinapoli L, Mingoia M, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolera-bility. J Neurol. 2011;258:2100-2104.
110. Merrell RT, Anderson SK, Meyer FB, Lachance DH. Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg. 2010;113:1176-1181.
111. Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol. 2009;93:349-354.
112. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology. 2006;67:10-13.
113. Vecht CJ, Wilms EB. Seizures in low-and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther. 2010;10:663-669.
114. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473-481. (Pubitemid 36876104)
115. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2003;2:404-409. (Pubitemid 36793932)
116. Yap KY, Tay WL, Chui WK, et al. Drug interactions between chemo-therapeutic regimens and antiepileptics. Clin Ther. 2008;30:1385-1407.
117. Maschio M, Albani F, Jandolo B, et al. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. J Neurooncol. 2008;90:217-221.
118. Butowski NA, Chang SM. General and neurological complications of targeted therapy. In: Grisold, W, Soffietti, R, eds. Handbook of Clinical Neurology. Edinburgh: Elsevier; 2012;105:937-945.
119. Bourg V, Lebrun C, Chichmanian RM, et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol. 2001;12:217-219. (Pubitemid 32223871)
120. Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drugs resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol. 2005;74:113-121. (Pubitemid 41478906)
121. Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy; focal cortical dysplasia and glioneuronal tumors. Neuroscience. 2003;118:417-429. (Pubitemid 36423257)
122. Bauer B, Hartz AM, Pekcec A, et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol. 2008;73:1444-1453. (Pubitemid 351574834)
123. Löscher W. Drug transporters in the epileptic brain. Epilepsia. 2007;48:8-13. (Pubitemid 46280513)
124. Baltes S, Fedrowitz M, Tortos CL, et al. Valproic acid is not a substrate for P-glycoproyein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther. 2007;320:331-343. (Pubitemid 46025748)
125. Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia. 2004;18:1246-1251. (Pubitemid 39023135)
126. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameters: anticonvul-sant prophylaxis in patients with newly diagnosed brain tumors. Neurology. 2000;54:1886-1893.
127. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizures prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79:1489-1494. (Pubitemid 39578871)
128. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;2:CD004424. Review.
129. Siomin V, Angelov L, Vogelbaum MA. Results of a survey of neurosur-gical practice patterns regarding the prophylactic use of antiepilepsy drugs in patients with brain tumors. J Neuro-Oncol. 2005;74:211-215. (Pubitemid 41478921)
130. Mauro AM, Bomprezzi C, Morresi S, et al. Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neurooncol. 2007;81:279-285. (Pubitemid 46165332)